Page 1

MF IA 08 Your ideas can change peoples’ lives


MEDICAL FUTURES INNOVATION AWARDS.2008 Tonights hosts the glamorous Melanie Sykes and the dapper David Mitchell

“Winning a Medical Futures Innovation Award brings validation and endorsement to the winner’s idea, project or business and significantly enhances the chances of clinical and commercial success.”



Arrival of His Royal Highness Prince Michael of Kent GCVO


Innovators Gallery


Welcome from hosts Melanie Sykes & David Mitchell


Dinner created by Anton Edelman


Charity Auction


Presentation of the Medical Futures Innovation Awards


Dessert & Coffee


Raffle Results


Networking and Innovators Gallery



All proceeds from the 2008 Awards dinner will be shared amongst tonight’s selected charity partners.



he Medical Futures Innovations Awards is a unique UK based awards process that helps healthcare professionals and academics turn their ideas into tangible solutions to improve patient care. By entering the Medical Futures process, front line clinicians and academics have the chance to pitch their ideas and businesses to a world-class panel of experts for advice, guidance and peer-review. As well as the critical recognition and endorsement of a Medical Futures Innovation Award, winners receive a bespoke package of support to turn ideas into viable propositions that have credibility with investors. This may include assistance in articulating their idea; securing funding; and introductions to professional and commercial contacts vital in taking their idea to the next level. Over the last twelve months, in partnership with many of the medical Royal Colleges and Associations, ideas have been encouraged from those best placed to generate them. Over 1000 ideas have been submitted via the website, in a number of therapy areas, including cancer; cardiovascular disease; dentistry & oral health; ENT & audiology; orthopaedics; and ophthalmology.

A shortlist of the best 100 entrants were invited to pitch their ideas to the Judges in a Dragon’s Den Style. The Judges comprised many of the world’s leading experts drawn from medicine, academia and business and their task was to compare each idea on its merit, irrespective of the stage of development - which ranged from concepts to implemented services and trading businesses. The main judging criterion was impact the innovation was likely to have on patient care. Other crucial criteria included novelty and viability (clinical, technical and commercial). Past winners have gained widespread publicity and introductions to investors and industry leaders and between them have secured over £80m of funding. Most importantly, many have gone onto become successful services or products that are now changing peoples’ lives. The Awards only happen thanks to the generous support of our forward-thinking sponsors and partners and so a big thank you goes out to them this evening. The HAC Grounds, London EC1Y 2nd December 2008


Inventor, Roger Armour tells the audience about his idea

Journalist and newsreader, Michael Buerk at the 2007 Awards

Orthopaedic Surgeon, Mr Peter Cox shouts about his new idea

The Positive Mental Attitude Football Team at the Innovators Gallery

Marjorie Wallace and Peter Snow at the 2007 Awards

Heart Pioneer, Sir Magdi Yacoub at the 2007 Awards

The Medical Futures Process H

ealthcare is the world’s leading industry, now worth over £2.5 trillion. From penicillin to beta blockers, and hip replacements to coronary stents, bright ideas from medics have historically led to vast improvements in patient care – and have brought significant commercial rewards. Sky Sunrise Presenter, Charlotte Hawkins at the 2007 Awards

Writer and comedian, Rowland Rivron at the 2007 Awards

Dr Phil Hammond hosts the daytime Innovation Awards 2007

Actress, Jane Asher at the 2007 Awards

Comedian, Rory Bremner at the 2007 Awards

Newsreader, Alastair Stewart OBE at the 2007 Awards

Yet Medical Futures’ proprietary research has shown that, of the successful ideas to have stemmed from medics, they often languished inside the innovators mind for 10 years or more before they hit the drawing board. Add to this the commercialisation lag and it means that it might be 20 or 30 years before a clinician’s idea benefits a patient, if ever. Whether this is because most innovators are fascinated by the journey of discovery and less so about the destination, or whether it is a case of trying to get somewhere without a roadmap is a discussion for another time. Looking back in history, Medical Futures identified that many of the most successful innovations often came to fruition thanks to a serendipitous interaction between the innovator and a successful businessman. Yet, many clinician ideas are ill-formed and far too early for industry or investment; hence the chance of successful fertilisation is slim.

Rory Bremner and Joanna Lumley OBE host the 2007 Awards


Trevor Phillips OBE at the 2007 Awards

Joanna Lumley and Robert Gaines-Cooper at the 2007 Awards

Medical Futures was founded in 2001 by a group of energetic clinicians keen to change this paradigm. From the outset, it was apparent that clinicians were

time poor, uninformed and sceptical of all but their own. A trust platform was needed that could bridge the chasm that existed between the clinical community and the commercial world. Whilst the Innovation Awards can help boost well formulated ideas, there is a clear lack of assistance for those poor at articulating their ideas. As a result the Medical Futures i2 Events were established, a series of unique fora at which clinicians and academics could network and learn the basics of intellectual property, design, business planning, regulatory and funding. Obviously no such event could teach creativity - but there was already plenty of that around! The forum acts as a catalyst to nurture and realise talent and potential. Most importantly it allows knowledge to be cross-fertilised beyond traditional geographic and organisational boundaries. So far, thousands of clinicians and academics have attended a Medical Futures event and yet evidence suggests that we are only scratching at the surface. Working closely with the Department of Health’s National Innovation Centre and the new i4i programme, and the creation of new routes to funding for those that need it most, Medical Futures continues to cement its position as one of the pre-eminent fora for catalysing medical innovation in the UK.


Case studies


Mr Roger Armour, Retired NHS Vascular Surgeon Winner of Best Innovation to Improve Global Healthcare 2003

POSITIVE MENTAL ATTITUDE FOOTBALL LEAGUE Janette Hynes, NHS Occupational Therapist Winner of Social Entrepreneurship Award 2007



oger’s story began more than forty years ago when, as a medical student in Pakistan, he was unable to afford an ophthalmoscope - a device that is used to examine the back of the eye to diagnose high blood pressure, diabetes and strokes. Although he had ideas of how to greatly simplify the instrument, making it affordable to all, like most inventors he had no idea how to develop his idea for the marketplace. In 2001, after his retirement from the NHS, a visit to Africa and seeing a child blinded by a preventable eye disease, spurred Roger on to making a prototype. “It took me six months to work out what to do. I then got some material from an art shop and made one. It looked such as mess I was certain it wouldn’t


work.” He tried it anyway - first on his wife. “To my amazement I could see the retinal vessels at the back of her eye. And then I examined the cat...”. Winning a Medical Futures Award catalysed Roger to turn the concept into a real product, called the Optyse™, a pocket sized, lens-free ophthalmoscope that sells for half the price of a conventional instrument. Following the Medical Futures Award, Judge Sir Richard Sykes likened the Optyse™ to “the wind up radio of healthcare” with the potential to save millions of people’s sight worldwide. Since that time a company was formed to commercialise the product which has now gained CE Marking and FDA approval and the Optyse™ is available to purchase at


he Positive Mental Attitude (PMA) Football League is an engaging social venture for sufferers of mental illness. Created by former professional footballer and coach, Janette Hynes in 2005, the PMA aims to help its players achieve better physical and mental health, thus enabling recovery and reintegration into the community. Since winning her Award, Janette’s London based pilot has been professionalised and a review of activities demonstrated that of the 350 participants in its first two years, a staggering 75% returned to meaningful education or employment as a result. The PMA League has now partnered with the Football Association, the Football Foundation and the NHS to ensure secure funding and a joined-up

approach to the use of football as a tool to help sufferers of mental illness. As part of her Award, Medical Futures has mentored Janette and her team and assisted the restructuring of the PMA from a London based activity into a scalable national activity with a growing waiting list of teams eager to join. A fly on the wall documentary is being filmed and is soon to be televised. This includes footage of the day Janette received a letter from the Queen, honouring her with an MBE for services to disability, as well as a friendly match between the PMA’s Hackney Football Club and the UK Parliamentary Football team.


Case studies


Charles Potter and team Winners of the Medical Futures Best Business Proposition 2007


lide Pharma has developed the Glide Solid Dose Injector (SDI™), a needle-free drug delivery systemthat injects drugs in a solid dosage form. A tiny pointed rod of medication is pushed into the skin using a simple, handheld, reusable device. The medication dissolves in the skin releasing the drug or vaccine to the systemic circulation. Volunteers prefer the system over needles because not only is there no risk of accidental needle stick injury and hence risk of spread of blood borne illnesses, but also delivery is over in a fraction of a second. Easy to use and requiring no specific training, the system is ideal for self-administration and because the solid medication has a longer shelf life and does not require refrigeration, the system is an ideal


platform for large vaccination programmes in the developing world. Within weeks of winning the Best Business Proposition at the Medical Futures Innovation Awards in 2007, specialty pharmaceutical company, Glide Pharma, raised £2.3 million of investment. Since that time, progress has been swift and a further £2.2m has been raised. The Glide SDI™ is being developed internally for several generic drug applications and, in parallel, has entered feasibility studies with five partners, including two of the top ten pharmaceutical companies, for delivery of their proprietary drugs or vaccines.

Dr Archie Brain

Consultant Anaesthetist & Inventor Winner of Medical Futures Lifetime Achievement Award 2007


r Archie Brain’s idea has affected 300 million people worldwide and has changed the way anaesthesia is carried out with his groundbreaking concept of the Laryngeal Mask Airway (LMA). Yet thirty years ago his idea was just a concept. Building prototypes in his Essex bedroom, he worked through the night studying airway anatomy and physiology, design materials and its safe clinical use. At one stage in taking his invention into work, it is said that one of the hospital cleaners reported him for what appeared to be a sideline in manufacturing exotic condoms. Dr Brain’s story is an almost classic example of the crazy inventor. Armed with prototypes built in his

bedroom he approached several experts and manufacturers only to have his idea rejected. Convinced and unswerving in his vision, Archie persisted for a number of years until he met a similarly visionary businessman who helped fund and commercialise it. The LMA has since revolutionised the practice of anaesthesia and improved the care of millions. In 2007, Dr Brain was recognised by his peers, endorsed jointly by the Royal College of Anaesthetists and the Association of Anaesthetists of Great Britain & Ireland and awarded a Medical Futures Lifetime Achievement Award for his contribution to medicine and for changing people’s lives.


The Cancer

Innovation Awards Children with Leukaemia Charity Registration no. 298405

CHILDREN with LEUKAEMIA was founded 21 years ago by Eddie and Marion O’Gorman in memory of their son, Paul, who died from leukaemia, and their daughter, Jean, who also lost her battle with cancer just nine months later. Losing a child is unimaginable and when I first heard about the O’Gormans’ double tragedy I was deeply touched and have been involved with the charity almost since the start. What started as a small memorial charity has become the leading UK charity dedicated to the conquest of childhood leukaemia. The charity invests vital funds for research into the causes of the disease, into finding new and improved treatments, and to the welfare of affected children and their families. In the last three years alone the charity has committed £15 million to research projects across the UK, in addition to providing a significant proportion of funding for a number of welfare programmes helping leukaemic children and their families. I strongly believe that we need to explore all possible avenues for new treatments and cures for this devastating disease and so we are delighted to associate with cancer innovation and put out a call for ideas to improve cancer care.

Linda Robson Trustee



The Cancer Innovation Awards JUDGES

The Royal College of Radiologists

The Cancer Innovation Awards are supported by an unrestricted educational grant from Pfizer Oncology, who is committed to advancing the scientific understanding of cancer, and to bringing new medicines to address unmet medical needs in cancer patients.

The Royal College of Radiologists’ role is to advance the science and practice of radiology and oncology, further public education and promote study and research. Professor Andy Adam President, Royal College Radiologists

Professor Michael Baum Professor Emeritus of Surgery, University College London

Dr Jane Barrett Dean of the Faculty of Clinical Oncology, Royal College Radiologists

Dr David Gillen Medical Director for Pfizer UK

Dr Alison Jones Chair, Association of Cancer Physicians Professor the Baroness Finlay of Llandaff President of the Royal Society of Medicine

Professor Robert Mansel Professor of Surgery, University of Wales College of medicine

Karol Sikora Medical Director, CancerPartners UK

Professor Mike Richards CBE National Cancer Director, Department of Health


PROSTATE CANCER MRI SCAN MRI to distinguish harmful from harmless prostate cancers

Winner of a Patient Care Innovation Award in the Cancer Innovation Awards Dr Chris Parker, Dr Nick Van As, and Professor Mandita De Souza, Royal Marsden Hospital, London This technology concept uses a special MRI scan of the prostate in an attempt to distinguish between harmful and harmless prostate cancers, and so reduce the need for biopsies. A blood test called prostate specific antigen or PSA is currently used to test for prostate cancer, and men with high PSA levels may then require a biopsy to check for cancer. Many prostate cancers are very slow growing, and even if detected, may never cause the patients any symptoms in their lifetime and hence certain patients are being treated unnecessarily. The technology has been tested in a pilot study of 86 men. Initial results suggest that the number of men undergoing biopsy could be reduced by half with no impact on the detection of harmful prostate cancers. The team is now seeking funding to carry out more detailed trials.

Point of care diagnostic device to detect bladder cancer


Judges Comments The Judges felt that this project demonstrated beautifully how technology could be used to improve service design and patient care and would like to see it developed further



Winner of a Translational Research Award in the Cancer Innovation Awards Dr Nick Miller-Jones, Lawrence Fenelon, UroSens Ltd, Cambridge This is a point of care test for diagnosing bladder cancer. It detects the presence of a special protein, a marker for bladder cancer in a urine sample. The main current method for diagnosing bladder cancer is cystoscopy, which involves passing an endoscope up the urethra and into the bladder under anaesthetic. The new test will be much cheaper, is non-invasive, and hopes to save many patients the need for a cystoscopy. Bladder cancer is the fifth most common cancer with high level of recurrence. The team hopes that the test could be used to monitor cancer patients and check for recurrence and in the long run, possibly become a screening tool. The test is undergoing clinical trials and should be available in two to three years.

Judges Comments The underlying technology behind this innovation won a previous Medical Futures Award and they are delighted to now see it advance and most importantly to find clinical utility. They are keen to see this enter into clinical trials.

PERSONALISED CANCER MEDICINES Winner of the Best Drug Discovery Technology Award in the Cancer Innovation Awards

Dr Christopher Torrance, Professor Alberto Bardelli, Dr Darrin M Disley, Dr Rob Howes and Dr Paul Morrill, Horizon Discovery Ltd, Cambridge This is a series of genetic techniques that can determine which groups of patients will respond to cancer drugs based on their genetic profile. The drug development process is very expensive and many drugs are found to be ineffective or have unacceptable side effects far too late in the process, often after hundreds of millions of pounds have been spent. A world-class team of scientists from Cambridge have developed a patent protected technique to help pharmaceutical companies know which patient groups will respond to their drugs much earlier on in development, and can also help them develop new classes of drugs tailored to the genetic characteristics of certain patient populations. They aim to bring personalised medicine closer to reality and are looking for strategic investors and collaborators.

Judges Comments The Judges felt that this technology would have significant potential to help pharmaceutical companies in drug development.


Winner of The Best Diagnostic Technology in the Cancer Innovation Awards Mohammed Keshtgar, Stephen G Bown, Santosh Somasundaram and Martin Austwick, Royal Free Hospital NHS Trust and University College London This is a medical device to speed up the diagnosis of breast cancer. During surgery, a lymph gland, called the sentinel node is taken from the armpit and sent to the laboratory to check for spread. If the gland is positive then the patient will undergo a second operation. A team from London have developed an optical scanner that can be used in operating theatres at the time of surgery. If positive, definitive surgery takes place there and then, saving up to a third of women the need to undergo a second operation. Unlike some other available methods, the lymph gland is not destroyed and so can be sent to the laboratory for further tests. The technology relies on light and elastic scattering spectroscopy that displays different optical signature between cancer and non cancerous cells.

X-Man Models to help pharmaceutical companies develop personalised medicines

Node Scanner to diagnose cancer at the speed of light

Judges Comments Whilst this is a very crowded space, it was felt that low cost and the fact that the sample was not destroyed were major benefits over competitive technologies. The Judges would like to see this project progress into a multi-centred trial.


The Cardiovascular Innovation Awards ChildreN’S HEART Federation

Since 2006 I have been a patron of a charity that is concerned with kids affected by Di George syndrome a symptom of which is congenital heart diseases. As a result I am really pleased to be able to extend my support to Children`s Heart Federation which leads the federation of organisations that care about children with heart defects and also provides direct help to affected kids and their families. Part of the remit of these charities is to support pioneering medical research and innovation that could put an end to the suffering caused by congenital heart disease, and hopefully the Medical Futures Innovation Awards will help these amazing advances to truly impact on patients’ lives. I hope that whilst you have a truly enjoyable evening you take a moment to think of those youngsters and their families affected by heart disease.


Charity Registration no. 1120557


Anthony Head Patron of Max Appeal An affiliate of the Childrens Heart Federation



The Cardiovascular Innovation Awards JUDGES

Since its formation in 1922 the society has set standards of excellence for individuals, organisations, and the care of patients wit S works in collaboration with patients, the public, and partner organizations and is committed to training and education. Dr Nicolas Boon President, British Cardiovascular Society

Dr Sarah Clarke Consultant Cardiologist and Clinical Director of Cardiac Services, Papworth Hospital

Mr Stewart Fox Managing Consultant, PA Consulting

Professor Sir Bruce Keogh Medical Director, the National Health Service

Professor Martin Rothman Consultant Cardiologist, Bart’s and The London NHS Trust

Winner of Best Technology in the Cardiovascular Innovation Awards

Dr Darrel Francis, Dr Zachary Whinnett, and Mr Keith Willson, Imperial College London

A pacemaker on a chest X-ray

Illustration of a human heart where cells will be implanted to restore areas of damage after a heart attack.


This is a new form of software using special algorithms to optimise the timings on a heart pacemaker so that it accurately mimics the contractions of the patient’s heart. Currently available techniques used to determine the optimal settings for pacemakers are unreliable, uncomfortable for the patient, time consuming and expensive. The new technology synchronises the pacemaker much more accurately and in just a few minutes and could be a bit like the “automatic fine tuning” button that improves pictures on analogue televisions. The technology aims to benefit patients by increasing their exercise capacity and reducing breathlessness. The team is looking to validate the technique and is seeking partnerships with device manufacturers.

Judges Comments The Judges felt this was an exciting development, but that it would be difficult to commercialise as a stand alone entity and are therefore keen to promote dialogue with relevant device manufacturers.

Senior Lecturer in Clinical Cardiology, University of Leicester

Professor Clifford Shearman Professor of Vascular Surgery, University of Southampton




Dr William Toff

HUMAN HEART-DERIVED PROGENTITOR CELLS FOR CARDIAC REGENERATION Winner of a Translational Research Award in the Cardiovascular Innovation Awards

Michael Schneider, Dorian Haskard, and Ranil de Silva, National Heart and Lung Institute, Imperial College London

BIOMIMETIC COATING FOR VASCULAR ACCESS GRAFTS Winner of a Best Biotechnology Award in the Cardiovascular Innovation Awards

Dr Shiv Sandhu, Simon Onis and Alan Rhodes of BioInteractions Ltd, Reading, Berkshire

This new technique uses heart stem cells to repair the damage to the cardiac muscle caused by heart disease. In a heart attack, heart muscle cells die, yet existing treatments don’t repair the damage to the muscle and have a limited effect on heart function. Professor Schneider was among the first to show that stem or progenitor cells exist in heart muscle, and then developed techniques to purify progenitor cells from a patient’s heart and grow them in the laboratory. The Imperial College team proposes to graft the human cells into injured cardiac muscle, under clinically relevant conditions, to obtain the safety and efficacy data needed to justify a phase I human trial. The team is seeking funding to support this essential bridge to clinical evaluation.

This biomaterials technology aims to reduce the rate of complications associated with dialysis. In patients with kidney failure, a tubular graft is implanted under the skin to connect an artery to a vein. This graft provides specialists with an access point to perform efficient dialysis. Complications relating to graft placement, repeated puncture and the presence of an artificial conduit can lead to complications including blood clots and infection. This team from Berkshire has developed new innovative coatings, derived from proven technologies. These proprietary technologies mimic components of the natural artery to render the graft infection free and free flowing for dialysis. The developers are seeking funding for clinical trials to enable the technology to benefit patients within three years.

Judges Comments

Judges Comments

The Judges felt that whilst there are many inherent risks with such early stage research, this is exactly the kind of translational research which should be funded as its potential impact is significant.

The Judges felt that this technology addressed a major unmet need, in that complications relating to infections and thrombosis of grafts cost the NHS significant sums. They would like to see this technology progressed into clinical trials.

The Judges wish to give special commendation to the following entries:

Intelligent Breathing

Dr Darrel Francis, Dr Charlotte Manisty, Mr Keith Wilson, Dr Resham Baruah, Imperial College London A device for people suffering from sleep apnoea. This new technology predicts apnoeas before they occur and prevents them with a tiny, carefullytimed dose of carbon dioxide which forces the patients to breathe.

Anti-microbial coating mode of action - contact kill of bacteria.

Shoulder Lifter for Cardiac Surgery

Dr Hazem Fallouh and Dr David Chambers, St Thomas’s Hospital, London A device to help lift the patient’s shoulders when undergoing open heart surgery. This new device helps reduce the tension that occurs when the breast bone is split open and then closed after surgery.

Biomimetic coating for vascular access grafts, BioInteractions Ltd (both above images)


Dentistry & Oral Health

Innovation Awards OPERATION SMILE Charity Registration no. 1091316 Operation Smile’s work has a deep resonance for me because I have spent time in children’s maxillofacial clinics with my first son and I have seen for myself the courageous and extraordinary young people we are thinking of tonight. We live in a cruel world where facial deformities can have a huge impact on young lives, and yet for a relatively small sum, lives can be transformed. When you consider that a new baby is born with a cleft and/or palate every two and a half minutes and it is the third most common birth defect, it’s clear the work of Operation Smile has only just begun. The charity works with partners in 51 countries around the globe, with more than 6000 medical volunteers performing in excess of 11,000 procedures each year. Operation Smile trains local medics in innovative techniques to allow them to provide on-going surgery, dentistry and speech therapy to patients year round and for as long as needed. Tonight is all about how innovative ideas can change lives. Your generosity can do the same, one smile at a time. Mishal Husain Patron



The Dental & Oral Health Innovation Awards JUDGES British Dental Association Founded in 1880, the BDA has over 20,000 members and is the professional association and trade union for dentists in the UK. The BDA develops policies to represent dentists working in all fields.

GSK’s mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Mary Lynn Bosma Medical Director Clinical Research Aquafresh, GSK

Professor Edward Lynch Professor of Restorative Dentistry and Gerodontology

Professor Damien Walmsley Professor of Restorative Dentistry, University of Birmingham

Winner of a Patient Safety Innovation Award in the Dentistry & Oral Health Innovation Awards Dr Frank Prior, Robert Smith, Dr. Adrian Coward, Synergy Health, Strathclyde, Scotland

Electro-Elution of staineless steel instruments

Electro-elution is a new cleaning method for stainless steel surgical instruments using electrolysis. It removes blood protein and bacteria much faster than traditional methods and also removes prion protein the agent believed to cause Creutzfeldt Jacob Disease (CJD). The method uses a standard basket that is used to clean surgical instruments, but it is negatively charged. Most proteins, including prions, are negatively charged and are therefore repelled off the surface of the instrument into the electrolyte where they are broken down, rendering them inactive. The team has developed a working prototype and have gathered much clinical evidence. They are in the process of licensing negotiations to start manufacturing.

Judges Comments

InfraRed imaging of a tooth


The Judges felt this was a novel idea and although initially tested in dentistry, they believed could have much wider application and want to see this progress into clinical trials.

Dean and Head of the King’s College London Dental Institute

Mr Gordon Watkins MBE President, British Dental Association



Professor Nairn Wilson CBE



Winner of Best Diagnostic Award in the Dentistry & Oral Health Innovation Awards Dr Christopher Longbottom, Prof John Girkin, Prof Nigel Pitts and Dr Simon Poland, Dundee University and Strathclyde University This is a medical device that will enable dentists to produce images of teeth, bones and gums similar to X-rays but by using Infrared light. The team has developed a novel instrument using a miniature camera and a set of mirrors to produce images of the teeth. This new imaging technique allows pictures to be taken without the risks associated with X-rays, of particular importance in children. The idea came about through collaboration between physicists and dentists and the hope is to enable dentists to monitor teeth and bones over time. InfraRed Imaging potentially has much wider application for example, in measuring bone density. The team is currently testing out their device in the laboratory and they are seeking funding to develop and test a clinical instrument.

Judges Comments The Judges were highly impressed by the potential of this technology and wish to see it progress and obtain further proof of concept.

The Judges wish to give special commendation to the following entries:

International Virtual Dental School (IVIDENT) Patricia A Reynolds, Joe Harper, Kate Hough, Professor Ken Eaton, and Mr. Sami Stagnell, Kings College London

IVIDENT aims to provide high quality, accessible, innovative and exciting dental education through a flexible online environment. Funded by HEFCE (Higher Education Funding Council for England) and the Department of Health, this three year educational research project aims to become a self-sustaining non-profit making enterprise.

Plaque Revealed

Immuno -therapeutic Prevention of Dental Decay

Dr Shauna Culshaw, University of Glasgow. Martin Taubman, The Forsyth Institute, Boston, USA (see page 35) This is a concept stage targeted therapeutic to reduce dental decay or caries, a major problem for society, especially for children in deprived areas. It aims to prevent the accumulation of one of the main bacteria thought to cause caries, mutans streptococci.

Plaque Revealed

Professor Susan Higham, Dr Chris Hope, Dr Monique Van Der Veen, and Dr Elbert De Josselin De Jong, Uniersity of Liverpool This is an ingenious use of quantitative lightinduced fluorescence (QLF) to visualise the early stages of tooth decay and demonstrate the amount of plaque on the teeth when a special blue light is shone onto them.


ENT & Audiology Innovation Awards Deafness Research UK Charity Registration no. 326915

I have been a Vice President of Deafness Research UK for some years now and I am proud to be part of its invaluable work. Most of us take our hearing for granted and yet, without it, there are invisible barriers to communication which too often leave people feeling isolated and alone. Nine million people in the UK and many millions more around the world suffer from hearing loss and related conditions. Deafness Research UK delivers world-class research which offers them hope - hope of radical improvements in prevention, diagnosis and treatment. The charity has already helped develop the technology used across the NHS to screen babies for deafness, isolated important genes for deafness and deaf-blindness and improved digital technology for hearing aids. There is much more to do. This association with Medical Futures and the ENT & Audiology Innovation Awards is timely and welcome. Ultimately we aim to find cures for these neglected conditions. With your help we are one step nearer. Have a good evening.

Dr Miriam Stoppard Vice President Deafness Research UK



The ENT & Audiology Innovation Awards JUDGES

Professor Pat Bradley National Clinician Lead, Head and Neck Cancer

Mr David Morgan Clinical Director of ENT Services, Heart of England NHS Foundation Trust

ENT UK aims to improve the care available to patients suffering from conditions of the ear, nose, throat, head and neck, and to promote the understanding of the range of conditions treated by the specialty. It provides information to the general public and media and encourages and supports research and continuing education.

Mr Andrew Swift Consultant ENT Surgeon, Aintree University Hospitals NHS Trust

Mr Guri Sandhu ENT Consultant, London

Mr Ghassan Alusi ENT Consultant, St.Bartholemew’s and The Royal London Hospitals, London Mr Kalpesh Patel Consultant Ear, Nose and Throat Surgeon, St Mary’s and Ealing Hospitals, London



AN EAR WORN SENSOR FOR HAND HELD HEARING TESTS REMOTE HEALTHCARE MANAGEMENT Winner of a Diagnostic Innovation Award Winner of a Translational Research Award in the ENT & Audiology Innovation Awards An ear-worn sensor for remote healthcare monitoring

Hand-held hearing tests

in the ENT & Audiology Innovation Awards

Professor Guang-Zhong Yang, Dr Benny Lo, and Dr Louis Atallah, Imperial College, London

Mr Jonathan Scotchbrook, Martin Simpson, Gary Norman and Jonathan Stuart, Sensaurial Ltd, Oxford

This is a medical device that is capable of detecting and recording information on a person’s movement and activity. It could transform the rehabilitation of surgical or stroke patients by enabling healthcare professionals to monitor a patient’s mobility and whether there is swaying or imbalance. It also has potential application in the care of the elderly. The device, which fits neatly behind the patient’s ear, processes information in real time, and transmits it to a remote database. The technology has been in development for four years and clinical trials have been carried out. A spin out company, Sensixa is now seeking funding to commercialise the device.

This is a medical device to improve the diagnosis of hearing loss. Every person has a specific hearing profile, however techniques currently used to measure hearing are limited, measuring only eight frequency points and also require a large hospital based laboratory, and can take up to half an hour to complete. A company from Oxford is developing a much simpler, hand-held device that uses a novel technology to measure hundreds of frequencies in less than 30 seconds. Pre-clinical trials have been very positive and the team is now seeking funding to commence clinical trials, with the aim of having a market ready device by the end of 2009.

Judges Comments The Judges felt that this is an exciting platform technology and recommend that the team focus on finding the right clinical applications and develop robust routes to market.


Judges Comments The Judges felt that this is a very exciting concept that needs to go through appropriate clinical trials, and if positive, they would like to see this brought to fruition in the shortest possible time.


Winner of a Surgical Training Innovation Award in the ENT & Audiology Innovation Awards Meredydd Harries and Anne Cureton, Royal Sussex County Hospital, West Sussex This is an innovative training tool to improve laryngeal surgical skills using a mannequin model. Trainees in laryngeal surgery currently have to learn by direct supervision at live surgery. A surgeon from West Sussex has spent over two years developing a model of a head and neck with vocal cord inserts that slot into the appropriate position in the mannequin. He experimented with numerous materials before he found one that mimics the characteristics of normal and diseased vocal cords, for example, with polyps or cancers. His model allows trainee surgeons to practice and be tested in both microinstrumentation and laser techniques before they operate on patients. This teaching tool has been validated, and they are seeking funding to make it widely available.

The Judges wish to give special commendation to the following entries:

Bone Drill for Cochleostomy Peter Brett, Aston University, Birmingham. Mr Andrew Reid, Mr Chris Coulson and Mr David Proops, Queen Elizabeth Hospital, UHB Trust, West Midlands, and Professor Mansel Griffiths, St Michaels Hospital, Bristol

A new technology to stop power drills in their tracks once the bone has been penetrated to prevent the drill from damaging soft tissues such as vital nerves or blood vessels. Laryngeal laser sugery trainer using a mannequin model

Judges Comments The model will allow trainers to monitor trainee’s progress and improve patient care. Although they believe that computer simulation models are likely to be the future, this model has significant current utility and is certainly at the forefront of innovation in ENT training.

Bone drill for cochleostomy


The Ophthmology Innovation Awards THE LOWE SYNDROME TRUST Charity Registration no. 1081241 I have been a Trustee of the Lowe Syndrome Trust since it was founded just over eight years ago and proud to be part of such a worthwhile cause. Lowe Syndrome is a devastating disease that affects thousands of boys born worldwide with symptoms including cataracts (either blind or partially sighted), stunted growth, poor muscle tone, rickets, scoliosis, arthritis (some never walk), kidney problems, epilepsy and mental impairment. In spite of these handicaps, the little boys have extremely happy and cheeky personalities. Sadly few become adults. The charity is very small but is now regarded as the main fund raiser in the world for medical research. To date, we have funded 12 research projects in the UK including Dundee University, Great Ormond Street Children’s Hospital, University College London, Institute of Ophthalmology, Imperial College London, Addenbrooke’s Hospital Cambridge and Manchester University. Projects funded in the USA include The Institute of California and most recently Purdue University. These projects are paving the way to finding better treatments and eventually a cure - with your help we are one step nearer. Have a great evening!

Jonathan Ross Lowe Syndrome Trust Trustee



The Ophthmology Innovation Awards JUDGES

Mr Winfried Amouaku Consultant Ophthalmic Surgeon, Queen’s Medical Centre, Nottingham Mr Larry Benjamin Consultant Ophthalmologist, Stoke Mandeville Hospital

Mr Simon Keightley Consultant Ophthalmologist, North Hampshire Hospital, Basingstoke Professor John Marshall

Royal College of Ophthalmologists The RCO is the professional body for ophthalmologists and is responsible for creating and maintaining standards in ophthalmic training and practice, training, research and continuing professional development. The RCO also helps educate the public in all matters relating to vision and the health of the human eye.

Mr Peter McDonnell Consultant Ophthalmic Surgeon, West Birmingham Hospitals NHS Trust Professor Miles Stanford

Chairman, Academic Department of Ophthalmology, St Thomas’ Hospital, London

Professor of Clinical Ophthalmology, Kings College London





Winner of the Best Education Award in the Ophthalmology Innovation Awards Sight-Sim to help children visualise how sight-impaired children see the world.

Ophthalmology electronic patient record system.

Professor Gordon Dutton, Dr Ruth Hamilton and Dr Michael Bradnam, Greater Glasgow and Clyde Health Board and Dr Paul Siebert, University of Glasgow

Robert Johnston, Cheltenham General Hospital NHS Foundation Trust, and and David Johnston, Medisoft Limited, Leeds

This is new software to help parents, teachers, carers and fellow pupils to visualise how sight impaired children see the world. A child’s visual acuity and other measurements are entered into a software programme and a digital photograph, for example of a teddy bear, is modified to enable the user to see the same image as they do. The technology could have wider applications, for use in elderly people with visual impairment and to help manufacturers, publishers and advertisers better understand their markets, for example by adjusting the colours or print size on books or on packaging. A prototype has been developed and tested with support from the Chief Scientist Office, and funding is now required to commercialise it.

An Ophthalmology doctor has developed an electronic patient records system for eye departments. The system was set up to overcome the frustrations of not being able to access the outcomes of his operations and other difficulties surrounding paper based notes. The system captures all of the required information around surgery and outpatient appointments and also includes information on glaucoma and diabetic eye disease. A company, Medisoft has been formed and in less than four years the team have managed to go from a standing start to covering almost all of the eye departments in the UK that have electronic patient records. Medisoft is carrying out a pilot to test the feasibility of paperless eye departments and have ambitious growth plans.

Judges Comments The Judges felt that this was a vast improvement on existing products on the market trying to do similar things. They would like to see this funded and exploited.


The RetVas system for diagnosing retinopathy of prematurity and diabetes.


Winner of The Best Business Award in the Ophthalmology Innovation Awards

The Judges wish to give special commendation to the following entries:

Judges Comments

Winner of a Translational Research Award in the Ophthalmology Innovation Awards Andrew McNaught: Gloucestershire Hospitals NHS Foundation Trust, Cheltenham and Andy Harvey, Heriot-Watt University, Edinburgh This is an imaging device, and analysis software, that can quantify the oxygen saturation in blood vessels in the retina at back of the eye. The new technique uses hyperspectral imaging, and will help in the detection, and management of eye disease such as diabetic retinopathy, glaucoma and macular degeneration. The ‘IRIS’ technology was originally developed for defence applications in association with Qinetiq. The new technology is non-invasive and a vast improvement over current methods which involve an injection of dye into the blood vessels. It could potentially be used as a screening tool in diabetic retinopathy, and also to determine the extent of nerve damage in glaucoma. The team is looking to commercialise the product.

The Judges felt this was an exemplar as to how electronic records should be developed, from the bottom up with clinical and technical collaboration, to exacting standards.

Judges Comments

RetVas, The Diagnositic Retinal Image Quantification Tool

Electronic redesign of hospital eye referrals

Clare Wilson, Kings College Hospital, London, Dr Jeffrey Ng, Imperial College London and Alistair Fielder, City University, London

Roshini Sanders, Peter Curry, Barbara Grant, Shyamanga Borooah, Queen Margaret Hospital, Dunfirmline

The Judges felt this was exciting research and would like to see it further validated in clinical situations.


Winner of Best Medical Device in the Ophthalmology Innovation Awards Mr Roger H Armour Retired Surgeon, Hertfordshire This is a handheld medical device used to examine the front of the eye and detect diseases such as acute glaucoma and cataracts. Slit lamps have been around for over 100 years but are large and complicated and cost up to £10,000, whereas Armour’s invention is a much simpler, miniature version and costs only £100. It works in a similar way to the original slit lamp, by illuminating a section of the eye which can then be seen in very small detail. It even has a digital camera to record pictures. Its size and affordability aims to make the product much more accessible by GP’s, medical students and healthcare workers in developing countries, and improve the pick up of sight threatening diseases such as acute glaucoma. Mr Armour now hopes to turn his home-made prototype into a market ready device.

Retinal oximetry using hyperspectral imaging

Prototype of the mini-slitlamp

Judges Comments The Judges previously gave an Award to Mr Armour in 2003 for a lens free ophthalmoscope which has since reached the market. They are keen to see his next invention similarly benefit patients.

The Moorfields Motion Displacement Test for the detection of glaucoma Moorfields Eye Hospital, London (See page 35).

The Moorfields MDT for detection of glaucoma



Innovation Awards JOINT ACTION

The BOA’s Orthopaedic Research Appeal Charity Registration no. 1066994 In 2004, following a road traffic accident in Morocco, I was left on a desert roadside with a shattered pelvis, internal bleeding and almost every bone in my body broken. Thanks to the ingenuity and resourcefulness of my friends, I managed to get back to the John Radcliffe in Oxford, where I was put back together, literally piece by piece. My arm is metal, my leg is metal and my pelvis is fairly metal but I am alive and for this reason, I cannot emphasize enough the importance of orthopaedics and how it can change people’s lives. From babies with club feet and dislocated hips to children with cancers and rare genetic disorders who have growth disturbance or fragile bones that break; from people like me who suffer from devastating accidents to elderly patients with arthritis, orthopaedics is likely to touch us all at some stage in our lives. From hip replacements to cartilage grafting, British Orthopaedic surgeons have in the past pioneered many exciting advances. Joint Action is the British Orthopaedic Association’s research appeal and for this reason, I am delighted to lend my support to put out a call for new ideas to find ways to improve care. Enjoy the night.

Martha Lane Fox Entrepreneur and Co-Founder



The Orthopaedic Innovation Awards JUDGES DePuy, a Johnson & Johnson company is a leading provider of treatments of the musculoskeletal system with products that include joint implants, trauma devices and biologics. DePuy has a philosophy of delivering excellence in design, quality and service.

Mr Stephen Cannon President, British Orthopaedic Association

Professor Mike Freeman Honorary Consultant Orthopaedic Surgeon, The London Hospital

Professor Damian Griffin Professor of Orthopaedics, University of Warwick

Mr John O’Dowd

Mr Jake Timothy Consultant Neurosurgeon, Leeds General Infirmary

British Orthopaedic Association Founded in 1918 the BOA now has over 4000 members and serves to bring relief to people suffering from injury or musculoskeletal disorder by advancing the science, art and practice of orthopaedic surgery.

Professor Keith Willett Professor of Orthopaedic Trauma, University of Oxford

Mr Christopher Walker

Consultant Orthopaedic Surgeon & Chairman, RealHealth Institute

President, British Orthopaedic Foot & Ankle Society




Mr Mohamed Khalid, Orthopaedic Surgeon, University of Alabama at Birmingham, USA, and Shafiq Pawaz, Director, Fiberlogix International Ltd

Cintra Jaggan-Vince and Dr. Jonathan Vince, Tobago Regional Health Authority


Winner of a Blue Sky Award in the Orthopaedic Innovation Awards

Shafiq Pawaz (left) & Mohamed Khalid, FRIEND

The Fracture Repair Implant Embedded Navigation Device or FRIEND is a medical device to detect movement in healing fractures. If a fracture has healed or fusion has taken place, there should be no movement. Surgeons are guided by X-ray appearances and patient symptoms but in some circumstances it is very difficult to tell when union has taken place. This new fibre optic wire technology can be embedded within orthopaedic implants or in healing bones to look for micro movements and help orthopaedic surgeons determine how well a fracture is healing and also to guide weight bearing. The team have to date carried out basic proof of concept work but are now looking for funding to take this to market.

Judges Comments

Cintra Jaggan-Vince demonstrating Clip & Pull


The Judges felt this could be a very useful clinical research tool but within certain clinical situations, such as spine surgery, it could have major clinical utility. They would like to see this progress through proof of concept.

Winner of a Patient Care Award in the Orthopaedic Innovation Awards

This is a device that helps to restore independence to people with disability. The device, developed by a nurse, arose when she was having difficulty getting dressed due to back pain, and her child suggested that she invent something to help her. After three and a half years of working on various designs, testing them out on family and friends, the first Clip & Pull Device, was developed. It has a special patented clip which has a very strong grip, but opens with a very gentle squeeze mechanism so that it can be used by people with arthritis. Once the clips are attached to clothes the user can pull up their underwear or trousers and zip up a jacket with ease. The product is currently being manufactured and sold in small numbers.

Judges comments The Judges felt that the clip mechanism was ingenious as it requires no power of grip to apply and so would be great help for suffers of stroke, arthritis or loss of a limb. They would like to see the inventor be given assistance to make this widely available.

Winner of the Best Business Proposition in the Orthopaedic Innovation Awards Professor Kevin Shakesheff, University of Nottingham. Michael Leek, Cheryl Hunter and Helen Cox, Regentec Ltd, Nottingham This is a polymer technology to make a liquid bone for use as bone graft during surgery. A team of scientists from Nottingham have developed a synthetic, biodegradable material which has the texture of toothpaste but when injected into the body hardens within 15 minutes, at body temperature and has similar characteristics to normal bone. Approximately 1.5 million bone graft procedures are performed annually worldwide. Many of these require bone to be taken from other parts of the body, or from other donors. Although there are many other synthetic materials on the market, they are difficult to shape and the new ‘injectable bone’ is a much simpler procedure, allowing bone voids to be filled with ease. The material is biodegradable allowing new bone to replace it gradually. The team is seeking funding for clinical trials.

Judges Comments The Judges felt that this was a platform technology with significant clinical utility. They particularly liked the fact that it did not heat up when inserted into the body like many other injectable substances.


Winner of a Translational Research Award in the Orthopaedic Innovation Awards Dr Robert Stevens, Rajshee Mootanah, Julian Fairman and Mansel Williams, Oxfordshire This is a nanotechnology coating technique to modify the surface of implants and create a ‘living interface’ between artificial implants and bone. This space-age technology adds micro and nano sized hair like structures to the surface which relieve stress on the implant. In addition there is the possibility of adding a multilayer coating containing biological substances, such as growth factors that can improve attachment. The technology is being spun out from the Science and Technology Facilities Council and although only at a concept stage for medical applications, feasibility studies have begun to develop nanofibre coatings for hip implants. This is a platform technology, which has a wide number of clinical applications and the team are looking for clinical collaborations to solve unmet needs.

Injectable bone

Electrospinning for orthopaedic implants

Judges Comments The Judges felt that this was a very exciting technology that could have wide clinical application, particularly in spinal surgery. 33

The Special Innovation Awards NOMINEES

THE MOORFIELDS MDT FOR GLAUCOMA DETECTION Commended in the Ophthalmology Innovation Awards

Mr. David Garway-Heath, Dr. Gay Mary Verdon-Roe, Mr. Ananth Viswanathan, and Professor Fred Fitzke, Moorfields Eye Hospital and the UCL Institute of Ophthalmology.

The Special

Innovation Awards DebRA UK

Charity Registration no. 1084958 DebRA UK, founded in 1978, is the national charity working on behalf of individuals and families affected by Epidermolysis Bullosa (EB), a rare genetic condition which causes the skin and internals linings of the body to blister and shear at the slightest friction, or even spontaneously. Blistering can also affect inner body linings; such as the mouth and oesophagus and, in its most advanced form can be fatal in infancy. There are at least 5,000 people living with this devastating condition in the UK and 500,000 worldwide. Because DebRA UK receives no government funding, the charity, and the families it supports, rely on the generosity of the public to carry out its vital work, improving lives and giving hope. DebRA UK funds an expert team of nurses and social care staff to work directly with families affected by EB and also commissions world-leading research to help find effective treatments and hopefully a cure. It is for this reason we are proud to associate with Medical Futures and the very special Awards for innovations to improve patient care. Have a great evening.

The Moorfields motion displacement test (MDT) is a software program for assessing the field of vision to detect glaucoma. The aim of the test is to tackle the global challenge of undiagnosed glaucoma. The MDT runs on a laptop computer and offers the advantages of portability, affordability and potential accessibility through the internet. The latest test strategy, developed with City University, London, takes 90 seconds per eye and is currently undergoing validation with three international centres. The team seeks to commercialise the technology on completion of the validation program in 2009. Future plans include the development of a paediatric version of the test in collaboration with Great Ormond Street Hospital, London.

Judges Comments The Judges believed that if the multicentre trials prove positive, that this could be an exciting tool with commercial utility and would like to see a robust implementation plan developed especially one that looks at reimbursement in the US.


Commended in the Ophthalmology Innovation Awards Dr Shauna Culshaw, University of Glasgow. Martin Taubman, The Forsyth Institute, Boston, USA. This is a concept stage targeted therapeutic to reduce dental decay or caries, a major problem for society, especially for children in deprived areas. This team has built a program to develop a vaccine for dental caries. They aim to identify proteins mediating immunity, which prevent the accumulation of caries-causing mutans streptococci in the oral bacterial biofilm, a bacteria proposed to be one of the major causes of dental caries especially in children. Although the work remains at a research stage, it is hoped that funding will be found to take the project forwards into manufacturing, clinical trials and ultimately to market.

Judges Comments The Judges were supportive of this work, providing that a mechanism was found to ensure that vaccination reached those that needed it most and the team could demonstrate a health economic model of cost effectiveness.

The National Institute for Health Research (NIHR) was established by the Department of Health to deliver ‘Best Research for Best Health’. This strategy includes increased support for innovation and the new innovation programme (i4i) will nurture novel ideas through the innovation process and turn them into practical healthcare applications. Medical Futures and the NIHR are piloting a scheme whereby relevant Awardees will be supported through the application process for i4i funding.

AN EAR WORN SENSOR FOR REMOTE HEALTHCARE MANAGEMENT Winner of a Translational Research Award in the ENT & Audiology Innovation Awards Professor Guang-Zhong Yang, Dr Benny Lo and Dr Louis Atallah, Imperial College, London See Page 24


Winner of the Best Drug Discovery Technology Award in the Cancer Innovation Awards Dr Christopher Torrance, Professor Alberto Bardelli, Dr Darrin, M Disley, Dr Rob Howes, and Dr Paul Morrill, Horizon Discovery Ltd, Cambridge. See Page 13


Winner of Best Diagnostic Award in the Dentistry & Oral Health Innovation Awards Dr Christopher Longbottom, Professor John Girkin, Professor Nigel Pitts and Dr Simon Poland, Dundee University and Strathclyde University. See Page 20


Winner of The Best Diagnostic Technology in the Cancer Innovation Awards Mohammed Keshtgar, Stephen G Bown, Santosh Somasundaram and Martin Austwick, Royal Free Hospital NHS Trust and University College London. See Page 13


Winner of a Blue Sky Award in the Orthopaedic Innovation Awards

Anthea Turner Patron


Mr Mohamed Khalid, Orthopaedic Surgeon, University of Alabama at Birmingham, USA, and Shafiq Pawaz, Director, Fiberlogix International Ltd See Page 32


The Best Business Proposition

NHS Technology Innovation Award


The Technology Strategy Board is a business-focused public body with a key role in driving innovation in the UK. Its vision is for the UK to be a global leader in innovation and a magnet for innovative businesses who can apply technology rapidly, effectively and sustainably to create wealth and enhance quality of life.

Mr Dr Ian Goldin Director, James Martin 21st Century School

Dr Dougal Goodman CEO, The Foundation for Science and Technology

The NHS Technology Innovation Award recognises clinical and commercial excellence emanating from the NHS. The National Innovation Centre (NIC), together with the nine regional Innovation Hubs and the new Training and Adoption Hubs, form an integrated core network that addresses the pressing need to foster and accelerate innovation in healthcare technologies and for this reason is proud to associate with this Award.

Mr Tom Ilube CEO, Garlik & Co-Founder Egg Internet Bank

Sir Anthony Jolliffe GBE Entrepreneur & Former Chair, Investment Advisory Board of ABN AMRO Ventures

Sir Christopher O’Donnell Pro-Chancellor, University of York

Ms Alison Wood Global Director of Strategy and Business Development, National Grid

Translational Research Innovation Award


Dr Christopher Torrance and Dr Darrin M Disley, Horizon Discovery Ltd

Professor Kevin Shakesheff, Helen Cox, and Michael Leek, Regentec Ltd

Jonathan Scotchbrook, Dr Gary Norman and Martin Simpson, Sensaurial Ltd


Winner of the Best Drug Discovery Technology Award in the Cancer Innovation Awards

Winner of the Best Business Proposition in the Orthopaedic Innovation Awards

Winner of a Diagnostic Innovation Award in the ENT & Audiology Innovation Awards

Horizon Discovery Ltd, Cambridge

Regentec Ltd, Nottingham

Sensaurial Ltd, Oxford

Horizon Discovery is a company developing next-generation medicines designed to individual patient needs. Horizon’s patented GENESIS™ technology has enabled the creation of more than 100 human cell lines that model how cancer ‘looks’ genetically in different patient populations. The development of a drug can take 15 years and cost more than £500m. X-MAN™ models enable pharmaceutical companies to dramatically shortcut the drug development process and predict success or failure at a much earlier stage, potentially saving hundreds of millions of pounds. A recent drug for lung cancer was found to only work in 10% of patients, a result that the Horizon technology could have predicted years before it entered into clinical trials. Despite being a start-up, Horizon Discovery is profitable and is already taking equity positions in exciting fast growing therapeutic companies.

RegenTec is a platform-to-product regenerative medicine company that is developing a broadrange of products to restore tissue & organ structure. RegenTec’s innovative proprietary technology comprises of a unique class of minimallyinvasive matrices, which can be combined to create structures with unique architectural, compressive and bio-resorptive properties. RegenTec’s initial product is in the orthobiological sector and is an injectable paste that is converted to a porous solid at body temperature. The resultant product does not generate heat and does not release toxic chemicals. It aims to simplify and shorten operating time and improve the quality of tissue repair in a range of different indications. The first product has been through initial pre-clinical trials and should be launched in the US during 2010. The company has several other exciting line extensions and is seeking funding to take the product through clinical trials.

Sensaurial is a sound technology company that has designed and developed a breakthrough in high-performance Digital Signal Processing (DSP) Technology. Sensaurial has the exclusive worldwide rights to exploit a new patented signal processing technology called ‘GAD Signal Processing’ (GSP) and the company’s initial offering is a hand-held device to carry out hearing tests that measure hundreds of frequencies in less than 30 seconds.

Judges Comments

Judges Comments

The Judges welcomed this as a breakthrough in drug discovery and would like to see pharmaceutical companies and regulators embrace the concept of personalised medicine.

The Judges felt that despite this being a very competetive marketplace there were several clear proposed advantages to this technology and are keen to see this enter into clinical trials.

Judges Comments This is an exciting, albeit early staged comany. With positive pre-clinical trials the focus must now be on obtaining the requisite clinical validation to demonstrate the market potential for this product.

The Translational Research Innovation Award recognises an individual or team that have translated basic research and applied it in the clinical setting, in order for it to benefit patients. The MRC promotes research into all areas of medical and related science with the aim of improving the quality of life of the UK public and contributing to the wealth of the nation. As such, the MRC is proud to sponsor this Award.

2008 Lifetime Achievement


The Medical Futures Lifetime Achievement Award is awarded to a clinician who has made a contribution of outstanding scientific or technical significance to the field of medicine and most importantly whose contribution has led to a marked and demonstrable improvement in patient care. The recipient of the 2008 Lifetime Achievement Award will be announced this evening.


WE ARE PROUD TO SUPPORT the 2008 Medical Futures Innovation Awards and all of tonight’s charities We wish the best of luck to all of the nominees and hope you have a fun and enjoyable evening.

Menu creative


As former Head Chef at the Savoy, I have cooked for many famous guests. The Queen Mother, The Queen, Princess Diana and President Clinton to name but a few. I have published ten books and made numerous TV and radio appearances, and I was also one of the first ever Judges on the BBC’s Masterchef.


I have won numerous Awards and honourary University degrees, and have taken part in world-wide food promotions at hundreds of locations such as the Oriental Bangkok, and the Four Seasons in LA. I am honoured to have received such recognition and accolade, but there is never a more special moment for me than when I am giving to help good cause. Tonight’s charities are all very special. They are all run by people who dedicate their lives to helping others and are challenged to find resources where resources are tight. I hope that you enjoy tonight’s meal and spare a moment, whilst sipping your champagne to think about all the needy children that tonight’s event aims to help. A small contribution from you by spending generously on raffle tickets and auction prizes can make a world of difference.


Anton Edelman Anton Edelman has recently opened Anton’s Restaurant at Great Hallingbury Manor Hotel near Bishop Stortford


Great Hallingbury Manor Anton’s Anton’s Lakeside Restaurant is located in the boutique hotel Great Hallingbury Manor, situated on the borders of Hertfordshire and Essex, overlooking a lake and bird sanctuary. The Laurent Perrier “Grand Siecle” chef’s table overlooks the hard working kitchen. With a wide array of contemporary dishes with a twist; using seasonal and locally sourced ingredients, and an extensive wine list selected personally by Anton, you can experience a true alternative, thrilling dining experience. Royal College Radiologists



MFIA Brochure 2008  

white mag FROM 2008